disease
🤖 AI-Generated

MS

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

5792Connections
30Hypotheses
3Analyses
50Outgoing
50Incoming
0Experiments
5Debates

No summary available yet.

🤖 AI-Generated

View on Wiki →

No AI portrait yet

Disease Info
Associated GenesAB, ACHE, ACSL4, AD, AGING, ALZHEIMER, ALZHEIMER'S DISEASE, AMYLOID
KG Connections550 knowledge graph edges
DatabasesOMIMOrphanetClinicalTrialsPubMed

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Ms

disease · 575 words

FEEMSA Study: Laryngopharyngeal Function in Neurodegenerative Diseases (NCT04706234)

clinical · 4197 words

Multiple Sclerosis (MS)

disease · 3824 words

MS4A4A Gene — Membrane-Spanning 4-Domains A4A

gene · 3294 words

MSA Genetics and Risk Factors

mechanism · 3275 words

Werner Wenning — PSP and MSA Researcher

researcher · 3115 words

Pathway Diagram

graph TD
    MS["MS"] -->|"causes"| DEMYELINATION["DEMYELINATION"]
    style DEMYELINATION fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#e0e0e0
    MS["MS"] -->|"causes"| NEURODEGENERATION["NEURODEGENERATION"]
    style NEURODEGENERATION fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#e0e0e0
    MS["MS"] -->|"causes"| AXONAL_DAMAGE["AXONAL_DAMAGE"]
    style AXONAL_DAMAGE fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#e0e0e0
    MS["MS"] -->|"regulates"| CNS["CNS"]
    style CNS fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    MS["MS"] -->|"associated"| OXPCS["OXPCS"]
    style OXPCS fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    MS["MS"] -->|"causes"| NEUROINFLAMMATION["NEUROINFLAMMATION"]
    style NEUROINFLAMMATION fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#e0e0e0
    MS["MS"] -->|"causes"| STING["STING"]
    style STING fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    STING_1["STING"] -->|"implicated in"| MS["MS"]
    style STING_1 fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    SPINK5["SPINK5"] -->|"associated"| MS["MS"]
    style SPINK5 fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#e0e0e0
    STS["STS"] -->|"associated"| MS["MS"]
    style STS fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#e0e0e0
    B_cells["B cells"] -->|"associated"| MS["MS"]
    style B_cells fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    INFLAMMATION_1["INFLAMMATION_1"] -->|"causes"| MS["MS"]
    style INFLAMMATION_1 fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#e0e0e0
    style MS fill:#ef5350,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0,font-weight:bold

Outgoing (623)

TargetRelationTypeStr
NEURODEGENERATIONcausesphenotype1.00
DEMYELINATIONcausesphenotype1.00
diseases-mshas_wikiwiki1.00
AXONAL_DAMAGEcausesphenotype0.79
OXPCSassociated_withprotein0.72

Incoming (5169)

SourceRelationTypeStr
diseases-msdescribed_bywiki1.00
SPINK5associated_withgene0.80
B cellsassociated_withcell_type0.80
STSassociated_withgene0.80
STINGimplicated_inprotein0.80

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
SNCA conformer propagation across PD, DLB, and MSA 0.820 multi Cross-disease neurodegeneration mechanis
SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso 0.734 neurodegeneration What molecular mechanisms link elevated
EZH2-Mediated H3K27me3 Spreading in Senescent ALS Microglia 0.714 als What are the mechanisms by which microgl
Loss of Homeostatic Epigenetic Identity Reprograms Microglia 0.650 neurodegeneration What molecular mechanisms drive microgli
Mitochondrial ROS from complex I and cardiolipin instability 0.640 neurodegeneration What mechanisms drive the self-amplifyin
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo 0.638 neurodegeneration CRISPR-based therapeutic approaches for
mutant FUS effects split between motor-neuron intrinsic stre 0.626 neurodegeneration Cell-Autonomous vs Non-Cell-Autonomous M
MFN2-PACS2 Axis at MAMs Coordinates Mitophagy-ER-Phagy Sync 0.615 neurodegeneration How do different organelle-specific auto
Cell-state stratification is required to resolve Cell-Autono 0.612 neurodegeneration Cell-Autonomous vs Non-Cell-Autonomous M
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration m6A RNA Modification and Alpha-Synuclein
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration Cell-Autonomous vs Non-Cell-Autonomous M
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration Sex-Specific Microglial States in Amyloi
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration Genetic Aging Landscape Variants and Epi
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration DPP6 GWAS Signal: Cell-Type Regulatory N
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration Causal Sequence of TDP-43 Nuclear Cleara
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration Proteogenomic Network Hubs as Druggable
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration Biophysical Determinants Shifting FUS/TD
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration VEGF Family GWAS Signals and Cerebrovasc
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration CCL2-CCR2 Axis at NMJ: Mechanism of Sele
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration Non-Neuronal Transcriptional Changes Pre
H4: Hyperconnected Hub Status Creates Proteostatic Traffic J 0.600 neurodegeneration Entorhinal cortex layer II vulnerability
Stratified falsifiers should govern Microglial Priming as Up 0.591 neurodegeneration Microglial Priming as Upstream Causal No
GPC4/HSPGs Collaborate with ApoE Isoforms to Dictate Tau Con 0.583 neurodegeneration What are the specific molecular determin
Gut-derived butyrate reprograms microglia for amyloid cleara 0.525 alzheimers Gut-Brain Axis Therapeutics for AD
REST-like neuronal silencing programs suppress MAPT in sever 0.506 neurodegeneration Which specific transcription factors med
Synthetic Biology Approach: Designer Mitochondrial Export Sy 0.505 neurodegeneration Mitochondrial transfer between neurons a
Synaptic Vesicle Protein Phosphorylation Reprograms Release 0.455 neurodegeneration Quantitative proteomics of the aging syn
Multi-Clock Ensemble Discordance as a Parkinson's Disease Pr 0.323 - Epigenetic clocks as biomarkers for Alzh
P2Y12 Receptor-Mediated Phase Resetting of Circadian Inflamm 0.000 - Can circadian interventions selectively
Temporal Modulation of Microglial Circadian Rhythms 0.000 - Synaptic pruning by microglia in early A

Mentioning Analyses (3)

Scientific analyses that reference this entity

How does lncRNA-0021 achieve sequence-specific binding to mmu-miR-6361 and what

molecular neurobiology | 2026-04-25 | 28 hypotheses Top: 0.865

What molecular mechanisms link elevated sphingomyelin synthase activity to incre

neurodegeneration | 2026-04-15 | 1 hypotheses Top: 0.734

What molecular mechanisms enable microglia to neutralize OxPC-mediated neurodege

neuroinflammation | 2026-04-13 | 2 hypotheses Top: 0.453

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (3)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple sys [PMID:9682846] Unknown Neuroscience letters 1998 0
Mutation in the alpha-synuclein gene identified in families with Parkinson's dis [PMID:9197268] Unknown Science (New York, N.Y.) 1997 0
Alpha-synuclein in Lewy bodies. [PMID:9278044] Unknown Nature 1997 0

Debates (5)

Multi-agent debates referencing this entity

How does lncRNA-0021 achieve sequence-specific binding to mmu-miR-6361 and what

closed · Rounds: 4 · Score: 0.66 · 2026-04-25

The study demonstrates that SGMS1 elevation correlates with increased Aβ and tha

closed · Rounds: 4 · Score: 0.75 · 2026-04-16

The abstract shows microglia ameliorate OxPC toxicity to neurons and oligodendro

closed · Rounds: 4 · Score: 0.68 · 2026-04-14

The abstract shows microglia ameliorate OxPC toxicity to neurons and oligodendro

closed · Rounds: 4 · Score: 0.62 · 2026-04-14

The abstract shows microglia ameliorate OxPC toxicity to neurons and oligodendro

closed · Rounds: 4 · Score: 0.92 · 2026-04-14

Related Research

Hypotheses and analyses mentioning MS in their description or question text

Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention for Severe Neurodevelo

Score: 0.638 · neurodegeneration · 2026-04-04

## Molecular Mechanism and Rationale The molecular foundation for acid-degradable lipid nanoparticle (ADP-LNP)-mediated

mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inf

Score: 0.626 · neurodegeneration · 2026-04-28

mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inflammatory signaling should produce a mea

MFN2-PACS2 Axis at MAMs Coordinates Mitophagy-ER-Phagy Sync

Score: 0.615 · neurodegeneration · 2026-04-21

**Molecular Mechanism and Rationale** The mitochondria-associated ER membranes (MAMs) represent specialized microdomain

Cell-state stratification is required to resolve Cell-Autonomous vs Non-Cell-Aut

Score: 0.612 · neurodegeneration · 2026-04-28

The question is likely underpowered or misleading unless analyses preserve the key strata: FUS, FUS-, ALS, NMJ. Averagin

Perturbation-first validation should precede therapeutic claims for m6A RNA Modi

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro

Perturbation-first validation should precede therapeutic claims for Cell-Autonom

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro

Perturbation-first validation should precede therapeutic claims for Sex-Specific

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro

Perturbation-first validation should precede therapeutic claims for Genetic Agin

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro

Perturbation-first validation should precede therapeutic claims for DPP6 GWAS Si

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro

Perturbation-first validation should precede therapeutic claims for Causal Seque

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro

Perturbation-first validation should precede therapeutic claims for Proteogenomi

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro

Perturbation-first validation should precede therapeutic claims for Biophysical

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro

Perturbation-first validation should precede therapeutic claims for VEGF Family

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro

Perturbation-first validation should precede therapeutic claims for CCL2-CCR2 Ax

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro

Perturbation-first validation should precede therapeutic claims for Non-Neuronal

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro